Dry formulations of vaccines that are room temperature stable
AssigneeIntervet Inc.
InventorsZhisong Qiao, Kevin O'Connell
Life of this patent
Estimating the term…
Abstract
The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
Claims20
A dry formulation of a vaccine that comprises a live attenuated virus, 30% to 80% (w/w) of a non-reducing oligosaccharide, 5% to 40% (w/w) of an amino acid stabilizer, 2% to 20% (w/w) of a protein stabilizer, and a buffer having a pH of 6.0 to 8.0;
- wherein the live attenuated virus is selected from the group consisting of a distemper virus, an adenovirus, a parainfluenza virus, and any combination thereof.
A method of making a dry formulation of a room temperature stable vaccine formulation comprising a live attenuated virus:
- a. preparing a vaccine formulation by combining a therapeutically effective amount of a live attenuated canine virus with 8% to 30% (w/v) of a non-reducing oligosaccharide, 1% to 6% (w/v) of a bulking stabilizer, 0.1M to 0.5 M of an amino acid stabilizer, 0.9% to 10% (w/v) of a protein stabilizer, and a buffer having a pH of 6.0 to 8.0;
- wherein the ratio of the bulking stabilizer to the non-reducing oligosaccharide is 0.05 to 0.40;
- and
- b. drying the vaccine formulation of step a. under vacuum to make a room temperature stable dry formulation;
- wherein the live attenuated virus is selected from the group consisting of a distemper virus, an adenovirus, a parainfluenza virus, and any combination thereof.
A dry formulation of a vaccine that comprises a live attenuated parvovirus, 10% to 80% (w/w) of a sugar alcohol, 10% to 70% (w/w) of a bulking stabilizer, 4% to 50% (w/w) of a protein stabilizer, and a buffer having a pH of 6.8 to 8.0.
Dependencies are inferred from the claim text.